Raptiva News
Psoriasis drug Raptiva withdrawn over fatal infection link
The manufacturer of the psoriasis drug Raptiva (efalizumab) has announced that it will begin the process to completely withdraw the drug from U.S. markets. Raptiva was approved by the Food and Drug Administration in 2003 as a weekly injection to treat cases of moderate to severe psoriasis. Genentech, the drug’s manufacturer, says Raptiva will no longer be available in the U.S. after June 8, 2009. More »
FDA warns of brain infection risk with Raptiva
The Food and Drug Administration has issued a public health advisory after receiving several reports of severe brain infections among patients taking the psoriasis drug Raptiva. The FDA said that it has received reports of progressive multifocal leukoencephalopathy (PML) among Raptiva users, including at least three deaths. More »
FDA orders “black-box” warning for Raptiva
The Food and Drug Administration has ordered the manufacturer of the psoriasis drug Raptiva to add a “black-box” warning to the drug’s label to warn patients of an increased risk of life-threatening infections while taking the drug. The FDA ordered the new warning after learning of several cases of serious infections among patients taking Raptiva. More »